Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: harrison cn. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743. Blood. 2022. PMID: 35007321 Free PMC article. Clinical Trial.
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Harrison CN, et al. N Engl J Med. 2005 Jul 7;353(1):33-45. doi: 10.1056/NEJMoa043800. N Engl J Med. 2005. PMID: 16000354 Free article. Clinical Trial.
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Brière J, Harrison CN, Green AR, Reilly JT. Campbell PJ, et al. Among authors: harrison cn. Blood. 2006 Mar 1;107(5):2098-100. doi: 10.1182/blood-2005-08-3395. Epub 2005 Nov 17. Blood. 2006. PMID: 16293597 Free article.
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.
Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdilès MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR. Campbell PJ, et al. Among authors: harrison cn. Blood. 2006 Nov 15;108(10):3548-55. doi: 10.1182/blood-2005-12-013748. Epub 2006 Jul 27. Blood. 2006. PMID: 16873677 Free article.
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T. Barosi G, et al. Leukemia. 2007 Feb;21(2):277-80. doi: 10.1038/sj.leu.2404473. Epub 2006 Nov 16. Leukemia. 2007. PMID: 17251900
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. Scott LM, et al. Among authors: harrison cn. N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202. N Engl J Med. 2007. PMID: 17267906 Free PMC article.
222 results